Bristol-Myers Squibb Stock: A Strong Buy Amid Oncology Success
Bristol-Myers Squibb released financial results for Q4 2024. Check out why I am upgrading BMY stock's rating from 'Buy' to ...
BMS’ Opdivo plus chemotherapy shows OS benefit in Phase III NSCLC study
Bristol Myers Squibb (BMS) has reported outcomes from the Phase III CheckMate -816 trial, indicating an overall survival (OS) benefit when Opdivo (nivolumab) is used with platinum-doublet chemotherapy ...
PMLiVE5d
Bristol Myers Squibb shares five-year results for Sotyktu in plaque psoriasis
Bristol Myers Squibb (BMS) has shared positive five-year results from a long-term extension (LTE) study of its oral TYK2 ...
Pharmabiz6d
Bristol Myers Squibb announces positive data from POETYK PSO LTE trial of Sotyktu to treat moderate-to-severe plaque psoriasis
Bristol Myers Squibb announces positive data from POETYK PSO LTE trial of Sotyktu to treat moderate-to-severe plaque psoriasis: Princeton, New Jersey Tuesday, February 18, 2025, 1 ...
appliedclinicaltrialsonline6d
Five-Year POETYK PSO Trial Results Show Sustained Efficacy, Safety with Sotyktu for Moderate-to-Severe Plaque Psoriasis
Five-year data from the POETYK PSO long-term extension trial confirm the sustained efficacy and safety of Sotyktu ...
Bristol Myers announces new five-year results from POETYK PSO trial
Squibb announced new five-year results from the POETYK PSO long-term extension, LTE, trial of Sotyktu treatment in adult ...
Bristol Myers Squibb’s Sotyktu shows consistent safety profile in psoriasis trial
US-based pharmaceutical company Bristol Myers Squibb (BMS) has reported results from the POETYK PSO long-term extension (LTE) ...
Bristol Myers reports no new safety signals observed in five-year Sotyktu data
Squibb announced new five-year results from the POETYK PSO long-term extension trial of Sotyktu treatment in adult patients ...
Le Lézard7d
New Five-Year Sotyktu (deucravacitinib) Data Show Consistent Safety and Durable Response Rates in Moderate-to-Severe Plaque Psoriasis
Bristol Myers Squibb today announced new five-year results from the POETYK PSO long-term extension (LTE) trial of Sotyktu (deucravacitinib) treatment in adult patients with moderate-to-severe plaque ...